Organogenesis Holdings Inc.
Organogenesis Holdings Inc. (ORGO) Financial Performance & Income Statement Overview
Explore the financials of Organogenesis Holdings Inc. (ORGO), including yearly and quarterly data on income, cash flow, and balance sheets.
Organogenesis Holdings Inc. (ORGO) Income Statement & Financial Overview
View the income breakdown for Organogenesis Holdings Inc. ORGO across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $86.69M | $126.66M | $115.18M | $130.23M |
| Cost of Revenue | $23.72M | $31.05M | $26.80M | $33.60M |
| Gross Profit | $62.97M | $95.61M | $88.38M | $96.63M |
| Gross Profit Ratio | $0.73 | $0.75 | $0.77 | $0.74 |
| R&D Expenses | $10.64M | $11.53M | $10.34M | $15.59M |
| SG&A Expenses | $72.51M | $73.86M | $71.80M | $76.54M |
| Operating Expenses | $83.15M | $85.39M | $82.14M | $92.13M |
| Total Costs & Expenses | $106.87M | $116.44M | $108.94M | $121.33M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $961000.00 | $0.00 | $471000.00 | $620000.00 |
| Depreciation & Amortization | $0.00 | $27000.00 | $4.40M | $4.20M |
| EBITDA | -$26.75M | $10.22M | $10.70M | -$9.72M |
| EBITDA Ratio | -$0.31 | $0.08 | $0.09 | -$0.07 |
| Operating Income | -$26.75M | $10.22M | $6.24M | -$13.89M |
| Operating Income Ratio | -$0.31 | $0.08 | $0.05 | -$0.11 |
| Other Income/Expenses (Net) | $963000.00 | $34000.00 | -$419000.00 | -$648000.00 |
| Income Before Tax | -$25.78M | $10.25M | $5.82M | -$14.54M |
| Income Before Tax Ratio | -$0.30 | $0.08 | $0.05 | -$0.11 |
| Income Tax Expense | -$4.19M | $2.58M | -$6.51M | $2.50M |
| Net Income | -$21.59M | $7.67M | $12.33M | -$17.04M |
| Net Income Ratio | -$0.25 | $0.06 | $0.11 | -$0.13 |
| EPS | -$0.17 | $0.05 | $0.09 | -$0.13 |
| Diluted EPS | -$0.17 | $0.04 | $0.09 | -$0.13 |
| Weighted Avg Shares Outstanding | $126.30M | $131.67M | $132.58M | $132.57M |
| Weighted Avg Shares Outstanding (Diluted) | $126.30M | $132.16M | $133.93M | $132.57M |
Over the past four quarters, Organogenesis Holdings Inc. demonstrated steady revenue growth, increasing from $130.23M in Q2 2024 to $86.69M in Q1 2025. Operating income reached -$26.75M in Q1 2025, maintaining a consistent -31% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$26.75M, reflecting operational efficiency. Net income dropped to -$21.59M, with EPS at -$0.17. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan